International Biophysics’ AffloVest Device Fuels Company’s Growth

International Biophysics’ AffloVest Device Fuels Company’s Growth

Austin-based International Biophysics Corporation recently announced that sales of its AffloVest device in the U.S. helped fuel revenue growth of 34% in 2016, in addition to the expansion of its global sales of surgical product lines.

AffloVest is the first truly portable, high frequency chest wall oscillation (HFCWO) vest designed for patients with respiratory conditions. The device addresses the medical needs of people with bronchiectasis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory diseases.

“As we enter our 25th year in delivering high-quality, innovative medical devices to patients in underserved markets, we are seeing rapid growth in our market share in both respiratory and surgical devices. Based upon results to date, we are highly confident that 2017 will continue and even exceed this trend of increased sales growth across all of our product offerings.” David Shockley, Jr., International Biophysics’ CEO, said in a press release.

The AffloVest tool is based on mechanical wave technology using eight individual oscillating motors inside the vest to effectively disrupt and mobilize mucus in the lungs. The vest helps clear the airways and subsequently helps prevent chest infections, while lessening breathing difficulty. AffloVest was introduced in the U.S. in late 2013.

“Through our sales and marketing efforts, we are building awareness for the AffloVest in the COPD patient population for bronchiectasis. We are pleased to see robust returns on our investments in infrastructure by moving production of the AffloVest from overseas to the United States and in growing our sales team here.” Shockley said.

Bronchiectasis is a chronic condition where the walls of the bronchi are thickened from inflammation and infection. Patients with the disease can suffer from repeated exacerbations (periodic flare-ups of breathing difficulties) that can develop slowly over a few weeks, or rapidly over a few days.

It is important for bronchiectasis patients to incorporate self-care strategies into daily life, including taking oral and inhaled medications. The use of airway clearance therapies, such as the AffloVest, can be a key part of the daily management of the disease.

International Biophysics recently showcased its AffloVest device at the Medtrade conference, held last month in Las Vegas.

Leave a Comment

Your email address will not be published. Required fields are marked *